Facebook
Twitter
LinkedIn
Forward
Effective Strategies for Treating and Managing Ocular Surface Health and Lid Margin Disease (CE Webcast)
Activity Description and Purpose
This educational activity will enhance optometrists' understanding of ocular surface disease and blepharitis, common but often overlooked inflammatory eye conditions. Optometrists will gain insight into the impact and selection criteria for supportive measures, such as artificial tears and lid wipes, practical guidelines for the diagnosis of blepharitis, and appropriate treatments based on clinical study data. Through case studies, presentations, and expert discussions, this activity will enable optometrists to review best practices in the diagnosis of blepharitis and develop individualized treatment plans for patients with blepharitis.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review best practices in the diagnosis of blepharitis
- Develop individualized treatment plans for patients with blepharitis
Faculty
 | Marc Bloomenstein, OD, FAAO (Chair) |
 | Mile Brujic, OD, FAAO |
 | Jaclyn Garlich, OD, FAAO |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any ineligible company. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Marc Bloomenstein, OD, is an advisory board member of AbbVie Inc, Alcon, Astellas Pharma Inc, Bausch & Lomb Incorporated, Bruder Healthcare, Harrow, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, Reichert, Inc, Sight Sciences, STAAR Surgical, Sun Pharmaceutical Industries, Inc, Sydnexis Inc, Tarsus Pharmaceuticals, Inc, Théa Pharma Inc, and Topcon Medical Systems, Inc; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Dompé US, Inc, Oyster Point Pharma, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc.
Mile Brujic, OD, is a consultant for AbbVie Inc, Apellis Pharmaceuticals, Astellas Pharma Inc, Bausch & Lomb Incorporated, Dopavision, Glaukos Corporation, MDelite Laser & Aesthetic, Tarsus Pharmaceuticals, Inc, Viatris Inc, Visionix, Visus Therapeutics, and ZeaVision LLC; and is on the speakers bureau for Bausch & Lomb Incorporated, Nordic Pharma, Tarsus Pharmaceuticals, Inc, Viatris Inc, and ZeaVision LLC.
Jaclyn Garlich, OD, is a consultant for Lumenis, Ophthalmic Resources Partners, and Théa Pharma Inc; is an advisory board member of AbbVie Inc, Alcon, Aldeyra Therapeutics, Bausch & Lomb Incorporated, Bruder Healthcare, Novartis Pharmaceuticals Corporation, and Tarsus Pharmaceuticals, Inc; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Dompé US, Inc, and Tarsus Pharmaceuticals, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant financial relationships with ineligible companies to disclose.
Accreditation Statement
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 95332-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 129791, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Tarsus Pharmaceuticals, Inc, and Théa Pharma Inc for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, Tarsus Pharmaceuticals, Inc, or Théa Pharma Inc.
This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 328.2
Available Credit
- 1.00 COPE